Sign in
Taking people in AustriaPhase 4

Tests two starting doses of aflibercept 8 mg in wet macular degeneration

Tests two starting doses of aflibercept 8 mg in adults with wet macular degeneration.

Key facts

Who runs it
Medical University Of Graz
Where
Graz, AustriaSee the site
Registry title
Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD
Status
Recruiting
Phase
Phase 4
People taking part
50 people, planned
Started
3 Mar 2026
Expected to end
31 Jan 2027
Type of study
Interventional
Record updated
16 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 or older with neovascular age-related macular degeneration (wet AMD) who have never been treated for it in the study eye.

Age
50 years or older on day 1.
Sex
All sexes can join.
Disease stage
Neovascular AMD of type 1 or 2. The choroidal neovascularization lesion must be nine or fewer disc areas. The diagnosis must be confirmed by fluorescein and/or indocyanine green angiography. Vision (BCVA) must be between 78 and 24 ETDRS letters on day 1.
Earlier treatment
The study eye must not have had any treatment for neovascular AMD before.

Main reasons for not taking part

  • Polypoidal choroidal vasculopathy (PCV) or type 3 AMD in the study eye
  • Cataract surgery within 3 months before day 1 or planned during the study, or any other eye surgery in the study eye
  • Other eye disease in the study eye that affects vision or causes fluid, such as retinal detachment or diabetic maculopathy
  • Pregnancy or breast-feeding, or current chemotherapy
  • Known allergy or intolerance to aflibercept 8 mg

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients must be ≥50 years old on day 1
  • All patients must be nAMD (neovascular age-related macular degeneration) treatment-naïve on the study eye
  • All AMDs must be type 1 or 2
  • Choroidal neovascularization lesion size have to be of nine or fewer disc areas
  • For each participant, one eye will be chosen as the study eye. Should eligibility apply to both eyes, the one with the lower BCVA during the screening will be selected
  • The diagnosis must be confirmed with fluorescein and/or indocyanine green angiography
  • The BCVA should be between 78 - 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters at day 1

Who cannot take part

  • Any cataract surgery within 3 months before day 1 or already scheduled during the study period on the study eye
  • Any other intraocular surgery on the study eye (e.g., pars plana vitrectomy, glaucoma surgery, corneal transplant)
  • Subjects who receive any intraocular surgery during the study period on the study eye
  • Current chemotherapy
  • >6 diopters of myopia on the study eye (For patients who have undergone previous refractive or cataract surgery, the preoperative refractive error should not have exceeded −6 diopters of myopia)
  • Known intolerance/hypersensitivity to aflibercept 8 mg
  • Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid (retinal detachment, diabetic maculopathy, epiretinal membrane with traction, central serous chorioretinopathy) on the study eye
  • Participation in another clinical trial during the last 4 weeks
  • Polypoidal choroidal vasculopathy (PCV) or type 3 AMD confirmed by fluorescein and/or indocyanine green angiography on the study eye
  • Simultaneous participation in another clinical trial
  • Pregnancy or breast-feeding
  • Retinal pigment epithelium (RPE) tear involving the macula on the study eye on day 1

Where in Austria

  • Medical University of GrazGraz, AustriaTaking people

About the trial

What the trial wants to find out

The primary aim of this study is to investigate how effective 2 aflibercept 8 mg loading doses lead to a non-active disease.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Two initial aflibercept 8 mg loading doses in treatment-naive neovascular AMD
Plain-language title
Tests two starting doses of aflibercept 8 mg in wet macular degenerationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
16 February 2026